Studies presented at AAIC 2019 have revealed the significant advances being made in the global search for blood-based biomarkers for dementia.
Browsing: Cognitive/neurodegenerative disorders
Observational studies reveal that use of sleep medications can increase an individual’s chances of developing dementia in sex-specific and race-specific ways.
Studies presented at AAIC 2019 provide potential treatment methods for the improvement of sleep quality in individuals with dementia.
New studies reported at AAIC 2019 are addressing the evolving and expanding role of technology in dementia care, prevention and alleviating burden.
New research into the LGBT community and risk of dementia have been reported at AAIC 2019, highlighting that the LGBT community may have a higher risk of cognitive decline.
Studies reported at AAIC 2019 have demonstrated the links between lifestyle factors and dementia; this information could provide new insight into the best ways to alleviate the likelihood of developing the disease.
Androgen deprivation therapy has been associated with a higher likelihood of developing dementia in men with prostate cancer when compared with individuals who are not exposed to the treatment.
Recent research at EAN 2019 suggests that the loss of ability to find one’s way, to keep track of time and to create and retrieve memories may all be hallmarks of Alzheimer’s disease.
A recently published study has suggested that certain anticholinergic medications, such as antidepressants and epilepsy drugs, may increase the risks of dementia later in life.
Nilvadipine has been demonstrated to increase blood flow to the hippocampus among people with Alzheimer’s disease, according to a recent study.